BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, Kim CM. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel). 2019;11. [PMID: 30781391 DOI: 10.3390/cancers11020230] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Kim TH, Lee WJ, Woo SM, Oh ES, Youn SH, Jang HY, Han SS, Park SJ, Suh YG, Moon SH, Kim SS, Kim DY. Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. Sci Rep 2020;10:21712. [PMID: 33303947 DOI: 10.1038/s41598-020-78875-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Lee SU, Yoon SM, Cheng JC, Kim TH, Kim BH, Park JH, Jung J, Tsai CL, Chiang Y, Park JW. Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe. Front Oncol 2021;11:646473. [PMID: 33718247 DOI: 10.3389/fonc.2021.646473] [Reference Citation Analysis]
3 Yang L, Si H, Ma M, Fang Y, Jiang Y, Wang J, Zhang C, Xiao H. LINC00221 silencing prevents the progression of hepatocellular carcinoma through let-7a-5p-targeted inhibition of MMP11. Cancer Cell Int 2021;21:202. [PMID: 33836753 DOI: 10.1186/s12935-021-01819-w] [Reference Citation Analysis]
4 Cozzi L, Comito T, Loi M, Fogliata A, Franzese C, Franceschini D, Clerici E, Reggiori G, Tomatis S, Scorsetti M. The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation. Technol Cancer Res Treat 2020;19:1533033820980412. [PMID: 33287650 DOI: 10.1177/1533033820980412] [Reference Citation Analysis]
5 Lewis S, Barry A, Hawkins M. Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.02.021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kim TH, Lee KS, Sim SH, Kim YJ, Kim DY, Chae H, Lee EG, Han JH, Jung SY, Lee S, Kang HS, Lee ES. Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis From Breast Cancer. Front Oncol 2021;11:783327. [PMID: 34804986 DOI: 10.3389/fonc.2021.783327] [Reference Citation Analysis]
7 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019; 25(31): 4360-4382 [PMID: 31496618 DOI: 10.3748/wjg.v25.i31.4360] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
8 Kobeissi JM, Hilal L, Simone CB 2nd, Lin H, Crane CH, Hajj C. Proton Therapy in the Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:2900. [PMID: 35740567 DOI: 10.3390/cancers14122900] [Reference Citation Analysis]
9 Kim TH, Park JW, Kim BH, Oh ES, Youn SH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. Front Oncol 2020;10:542. [PMID: 32411594 DOI: 10.3389/fonc.2020.00542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Yoo GS, Yu JI, Park HC. Current role of proton beam therapy in patients with hepatocellular carcinoma. Int J Gastrointest Interv 2021;10:175-82. [DOI: 10.18528/ijgii210043] [Reference Citation Analysis]